Business Daily from THE HINDU group of publications
Friday, May 18, 2007
ePaper
Business Daily from THE HINDU group of publications Friday, May 18, 2007 ePaper |
|
|
|
|
|
|
|
Corporate Results
-
Pharmaceuticals Dabur Pharma Q4 net rises to Rs 2.72 cr Our Bureau
New Delhi May 17 Dabur Pharma has reported increase significant rise net profit for the fourth quarter ended March. The company on Thursday announced net profit of Rs 2.72 crore for the period under review, against Rs 20.62 lakh for the corresponding previous period. Net sales grew 12.4 per cent to Rs 59.60 crore (Rs 53.01 crore). Mr Ajay Vij, CEO, said that the figures are the result of a healthy product mix with better margins. They also take into account reduced R&D expenditure. "Our average R&D expenditure is about 11 per cent; in the last quarter it was eight per cent. However, this is only temporary and we expect to increase R&D spends in the near future," said Mr Vij. For 2006-07, the company saw net profit growth of 36 per cent to Rs 25.25 crore (Rs 18.54 crore). Net sales for the year rose 19 per cent to Rs 322 crore (Rs 270 crore). The sale of the non-oncology division in February to Alembic for Rs 159 crore will be reflected only in the coming quarter. The company is also in the process of filing with regulators in the markets of Western Europe and the US to market its drug delivery system for Paclitaxel (Nanoxel)," said Mr Vij.
More Stories on : Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|